Patents by Inventor Evelina Angov

Evelina Angov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinantly expressed plasmodium CelTOS antigen and methods of use thereof
    Patent number: 9683024
    Abstract: A synthetic nucleotide, which transcribes as the cell-traversal protein for ookinetes and sporozoites (CelTOS) antigen of Malaria Plasmodium, and methods of use thereof.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: June 20, 2017
    Assignee: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY
    Inventors: Evelina Angov, Elke Bergmann-Leitner, Christian Ockenhouse
  • Recombinantly Expressed Plasmodium CelTOS Antigen and Methods of Use Thereof
    Publication number: 20160031953
    Abstract: A synthetic nucleotide, which transcribes as the cell-traversal protein for ookinetes and sporozoites (CelTOS) antigen of Malaria Plasmodium, and methods of use thereof.
    Type: Application
    Filed: July 20, 2015
    Publication date: February 4, 2016
    Inventors: Evelina Angov, Elke Bergmann-Leitner, Christian Ockenhouse
  • Recombinantly expressed CelTOS antigen and methods of use thereof
    Patent number: 9120868
    Abstract: A synthetic nucleotide, which transcribes as the cell-traversal protein for ookinetes and sporozoites (CelTOS) antigen of Malaria Plasmodium, and methods of use thereof.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: September 1, 2015
    Assignee: The United States of America as Represented by the Secratary of the Army
    Inventors: Evelina Angov, Elke Bergmann-Leitner, Christian Ockenhouse
  • Malaria vaccine
    Patent number: 8501926
    Abstract: The present invention features immunogenic compositions based on pre-fertilization or post-fertilization antigens expressed in the circulating gametocytes in the peripheral blood of infected persons or on the malaria parastes' stages of development in the mosquito midgut including extracellular male and female gametes, fertilized zygote and ookinete. The invention also features methods to prevent the transmission of malaria using the immunogenic compositions of the invention.
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: August 6, 2013
    Assignees: The Johns Hopkins University, The United States of America, as represented by the Secretary of the Army
    Inventors: Nirbhay Kumar, Evelina Angov
  • CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines
    Patent number: 8470560
    Abstract: The invention is an DNA vaccine and method of use thereof for modulating the immune response against the circumsporozoite protein (CSP) of malaria parasites, using the CR2 binding motifs of C3d, especially p28.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: June 25, 2013
    Assignee: The United States of America as Represented by the Secretary of the Army
    Inventors: Elke S. Bergmann-Leitner, Evelina Angov, George C. Tsokos
  • Isolation and purification of merozoite protein-1vaccine
    Patent number: 8298546
    Abstract: In this application is the expression and purification of a recombinant Plasmodium falciparum (3D7) MSP-142. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: October 30, 2012
    Assignee: The United States of America as Represented by the Secretary of the Army
    Inventors: Jeffrey A. Lyon, Evelina Angov
  • RECOMBINANTLY EXPRESSED PLASMODIUM CelTOS ANTIGEN AND METHODS OF USE THEREOF
    Publication number: 20120237538
    Abstract: A synthetic nucleotide, which transcribes as the cell-traversal protein for ookinetes and sporozoites (CelTOS) antigen of Malaria Plasmodium, and methods of use thereof.
    Type: Application
    Filed: November 23, 2009
    Publication date: September 20, 2012
    Inventors: Evelina Angov, Elke Bergmann-Leitner, Christian Ockenhouse
  • Expression, purification and uses of a plasmodium falciparum liver stage antigen 1 polypeptide
    Patent number: 8268615
    Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) LSA-NRC polypeptide. The method of the present invention produces a highly purified polypeptide which is useful as a vaccine and as a diagnostic reagent.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: September 18, 2012
    Assignee: The United States of America as Represented by the Secretary of the Army
    Inventors: David E. Lanar, Collette J. Hillier, Jeffrey A. Lyon, Evelina Angov, Sanjai Kumar, William Rogers, Arnoldo Barbosa
  • Recombinant merozoite protein-1vaccine
    Patent number: 8211447
    Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (FVO) MSP-142. The method of the present invention produces a highly purified protein that retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Grant
    Filed: July 21, 2009
    Date of Patent: July 3, 2012
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Evelina Angov, Jeffrey A. Lyon, Christian Asare Darko, Joe D. Cohen
  • MALARIA VACCINE
    Publication number: 20110171266
    Abstract: The present invention features immunogenic compositions based on pre-fertilization or post-fertilization antigens expressed in the circulating gametocytes in the peripheral blood of infected persons or on the malaria parastes' stages of develop-ment in the mosquito midgut including extracellular male and female gametes, fertilized zygote and ookinete. The invention also features methods to prevent the transmission of malaria using the immunogenic compositions of the invention.
    Type: Application
    Filed: July 22, 2009
    Publication date: July 14, 2011
    Applicants: THE JOHNS HOPKINS UNIVERSITY, The Government of the United States, as represented by the Secretary of the Army
    Inventors: Nirbhay Kumar, Evelina Angov
  • CR-2 Binding Peptide P28 as Molecular Adjuvant for DNA Vaccines
    Publication number: 20100255075
    Abstract: The invention is an DNA vaccine and method of use thereof for modulating the immune response against the circumsporozoite protein (CSP) of malaria parasites, using the CR2 binding motifs of C3d, especially p28.
    Type: Application
    Filed: October 3, 2008
    Publication date: October 7, 2010
    Inventors: Elke S. Bergmann-Leitner, Evelina Angov, George C. Tsokos
  • Isolation and Purification of P. Falciparum Merozoite Protein-142 Vaccine
    Publication number: 20100239614
    Abstract: In this application is the expression and purification of a recombinant Plasmodium falciparum (3D7) MSP-142. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Application
    Filed: September 29, 2009
    Publication date: September 23, 2010
    Inventors: Jeffrey A. Lyon, Evelina Angov
  • Expression, purification and uses of a plasmodium falciparum liver stage antigen 1 polypeptide
    Publication number: 20100040640
    Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) LSA-NRC polypeptide. The method of the present invention produces a highly purified polypeptide which is useful as a vaccine and as a diagnostic reagent.
    Type: Application
    Filed: May 14, 2009
    Publication date: February 18, 2010
    Inventors: David E. Lanar, Collette J. Hillier, Jeffrey A. Lyon, Evelina Angov, Sanjai Kumar, William Rogers, Arnoldo Barbosa
  • RECOMBINANT P. FALCIPARUM MEROZOITE PROTEIN-142 VACCINE
    Publication number: 20100028386
    Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (FVO) MSP-142. The method of the present invention produces a highly purified protein that retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Application
    Filed: July 21, 2009
    Publication date: February 4, 2010
    Applicant: United States Army Medical Research Command,
    Inventors: Evelina Angov, Jeffrey A. Lyon, Christian Asare, Joe D. Cohen
  • Isolation and purification of merozoite protein-142 vaccine
    Patent number: 7595191
    Abstract: In this application is the expression and purification of a recombinant Plasmodium falciparum (3D7) MSP-142. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Grant
    Filed: January 24, 2005
    Date of Patent: September 29, 2009
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Jeffrey A. Lyon, Evelina Angov
  • Recombinant merozoite protein-1vaccine
    Patent number: 7563883
    Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (FVO) MSP-142. The method of the present invention produces a highly purified protein that retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Grant
    Filed: August 14, 2007
    Date of Patent: July 21, 2009
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Evelina Angov, Jeffrey A. Lyon, Christian Asare Darko, Joe D. Cohen
  • Expression, purification and uses of a liver stage antigen 1 polypeptide
    Patent number: 7550275
    Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (3D7) LSA-NRC polypeptide. The method of the present invention produces a highly purified polypeptide which is useful as a vaccine and as a diagnostic reagent.
    Type: Grant
    Filed: November 12, 2003
    Date of Patent: June 23, 2009
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventors: David E. Lanar, Collette J. Hillier, Jeffrey A. Lyon, Evelina Angov, Sanjai Kumar, William Rogers, Arnoldo Barbosa
  • Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell
    Publication number: 20080076161
    Abstract: The present invention provides a method for modifying a wild type nucleic acid sequence encoding a polypeptide to enhance expression and accumulation of the polypeptide in the host cell by harmonizing synonymous codon usage frequency between the foreign DNA and the host cell DNA. This can be done by substituting codons in the foreign coding sequence with codons of similar usage frequency from the host DNA/RNA which code for the same amino acid. The present invention also provides novel synthetic nucleic acid sequences prepared by the method of the invention.
    Type: Application
    Filed: October 15, 2007
    Publication date: March 27, 2008
    Inventors: Evelina Angov, Jeffrey Lyon, Randall Kincaid
  • Recombinant P. falciparum merozoite protein-1 42 vaccine
    Publication number: 20080075741
    Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (FVO) MSP-142. The method of the present invention produces a highly purified protein that retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Application
    Filed: August 14, 2007
    Publication date: March 27, 2008
    Applicant: United States Army Medical Research and Command
    Inventors: Evelina Angov, Jeffrey Lyon, Christian Darko, Joe Cohen
  • Recombinant merozoite protein-142 vaccine
    Patent number: 7306806
    Abstract: In this application is the expression and purification of a recombinant Plasmodium falciparum (3D7) MSP-142. The method of the present invention produces a highly purified protein which retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: December 11, 2007
    Assignee: United States of America as represented by the Secretary of the Army
    Inventors: Jeffrey A. Lyon, Evelina Angov, Joe D. Cohen, Gerald Voss